---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-006495"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-09-18T23:59:59+00:00"
generated_at: "2026-05-31T03:59:20.334887+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma receives Nasdaq minimum bid deficiency; ineligible for cure due to reverse splits

## Summary
- Nasdaq notified CNS Pharma on Sept 12, 2024 that common stock failed to maintain $1.00 minimum bid for 30 consecutive days.
- Company ineligible for 180-day cure period because it effected reverse stock splits with cumulative ratio >=250 in prior two years.
- Company intends to request a hearing before Nasdaq Panel; request will automatically stay any suspension/delisting pending hearing.
- No assurance that Panel will grant an extension or that company will ultimately regain compliance with listing requirements.

## SEC filing metadata
- accession: 0001683168-24-006495
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-09-18T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824006495/0001683168-24-006495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824006495/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-006495
- JSON: https://secwatch.observer/filing/0001683168-24-006495.json
- Plain text: https://secwatch.observer/filing/0001683168-24-006495.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.